Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Red~Oneon Jun 09, 2021 6:22pm
160 Views
Post# 33359768

RE:Those who assume Reverse Split is the solution are naive

RE:Those who assume Reverse Split is the solution are naiveFrom previous post:" However, there are companies which have done RS accompanied with good PR's who succeeded. In my opinion, CLAS is the exception of the rule and will succeed. So, wait and see what happens after 17 June, before judging."

The only one that I know that was a penny stock that lived thru a split was BLR and the big difference there is that they have good management, a plan and a product. 

CLAS have none of that, other than a potential world changing drug that has yet to be proved and yet to be licensed by CLAS for it's intended use. Like a hunded or so other Pharma penny stocks . Promises 

So to say , wait and see after the AGM might be too late, to deterrmine if there is to be a R/S. After all it is up for a vote.
<< Previous
Bullboard Posts
Next >>